Protein kinases are important regulators of cellular proliferation and several, such as HER-2/neu, and the epidermal growth factor receptor (EGFR), have been implicated in the pathogenesis and progression of human breast cancer. We have speculated that other kinases expressed in breast cancer cells may have important functions in the genesis or maintenance of the malignant state. For this reason, we have completed a search for novel kinases in breast cancer tissue and have identified several potentially important species: Our work with the focal adhesion kinase (FAK) is among the more advanced subprojects. We have found that FAK expression is correlated with the invasive and metastatic phenotype and thus may represent a useful marker in early stage breast cancer. Moreover, specific attenuation of FAK expression by antisense oligonucleotides induces apoptosis in cancer cell lines making FAK a rational target for gene directed therapeutics. rak is a src related tyrosine kinase with a nuclear localization signal within its SH2 domain, rak is a unique nuclear tyrosine kinase that binds to the retinoblastoma gene protein, Rb, through its SH3 domain. This implicates rak in cell cycle control and potentially in transformation. STK1 is the human homolog of the cdc2 activating kinase (CAK) which is essential for cdc2/cyclin function. Our investigations show that inhibition of CAK expression results in attenuation of growth in a breast cancer cell line. TK5 is a new JAK kinase, JAK3, expressed in primary breast cancer cells and cell lines, and which is also the important kinase partner for the IL-2/IL-4 receptor. Our discovery of different splice forms with one leading to an enzymatically inactive JAK3 kinase suggests complex signalling through potentially novel cytokine receptors. In this proposal we will focus upon FAK, rak and CAK, characterizing the role of these novel species in breast cancer biology especially in growth and differentiation and to using this knowledge in the design of more specific and directed therapies for breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-08
Application #
6203251
Study Section
Project Start
1999-08-05
Project End
2001-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications